Review



dmcm  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Tocris dmcm
    Measurement of inhibitory synaptic transmission in slice preparations and effects of drug administration on OD plasticity in DGLα-KO mice (A) Whole-cell patch-clamp recording was performed in L2/3 and L4 pyramidal neurons in mouse V1 slices. (B) Representative mIPSC traces from L2/3 (P17) and L4 (P21) in wild-type and DGLα-KO mice. (C and D) mIPSC frequency (C) and amplitude (D) in L2/3 (WT, n = 28 (P17), 17 (P21), and 16 (P26) cells; KO, n = 31 (P17), 17 (P21), and 13 (P26) cells) and in L4 (WT, n = 25 (P17), 23 (P21), and 21 (P26) cells; KO, n = 25 (P17), 16 (P21), and 14 (P26) cells). Colored circles show data from individual cells. The black horizontal bar and error bars indicate mean and 95% CI, respectively. (E) <t>DMCM,</t> an inverse agonist of <t>the</t> <t>GABA</t> A receptor, was intraperitoneally injected into DGLα-KO mice during MD until 9 hours before the recording. (F) DMCM treatment was performed at P17-P21. Raincloud plots show the OD distribution after MD in nontreated (noDMCM, n = 482 (all), the same data as P21 KO-MD in <xref ref-type=Figure 2 A) and DMCM-treated DGLα-KO mice (DMCM, n = 619 (all), 79 (L2/3), 91 (L4), and 266 (L5) units in 6 mice). (G) DMCM treatment was performed at P13-P17. Raincloud plots show the OD distribution after MD in nontreated (noDMCM, n = 526 (all), the same data as P17 KO-MD in Figure 2 A) and DMCM-treated DGLα-KO mice (DMCM, n = 473 (all), 96 (L2/3), 60 (L4), and 186 (L5) units in 6 mice). (H) A cannabinoid receptor agonist, WIN was injected into DGLα-KO mice intraperitoneally during MD until the day before the recording experiment. (I) OD distributions of WIN-treated DGLα-KO mice without MD (noMD, n = 498 (all), 81 (L2/3), 66 (L4), and 203 (L5) units in 5 mice) and with MD (MD, n = 589 (all), 133 (L2/3), 114 (L4), and 201 (L5) units in 6 mice). Permutation test was performed in (C), (D), (F), (G) and (I) (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). See also Figure S3 . " width="250" height="auto" />
    Dmcm, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dmcm/product/Tocris
    Average 93 stars, based on 8 article reviews
    dmcm - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Layer specific regulation of critical period timing and maturation of mouse visual cortex by endocannabinoids"

    Article Title: Layer specific regulation of critical period timing and maturation of mouse visual cortex by endocannabinoids

    Journal: iScience

    doi: 10.1016/j.isci.2024.110145

    Measurement of inhibitory synaptic transmission in slice preparations and effects of drug administration on OD plasticity in DGLα-KO mice (A) Whole-cell patch-clamp recording was performed in L2/3 and L4 pyramidal neurons in mouse V1 slices. (B) Representative mIPSC traces from L2/3 (P17) and L4 (P21) in wild-type and DGLα-KO mice. (C and D) mIPSC frequency (C) and amplitude (D) in L2/3 (WT, n = 28 (P17), 17 (P21), and 16 (P26) cells; KO, n = 31 (P17), 17 (P21), and 13 (P26) cells) and in L4 (WT, n = 25 (P17), 23 (P21), and 21 (P26) cells; KO, n = 25 (P17), 16 (P21), and 14 (P26) cells). Colored circles show data from individual cells. The black horizontal bar and error bars indicate mean and 95% CI, respectively. (E) DMCM, an inverse agonist of the GABA A receptor, was intraperitoneally injected into DGLα-KO mice during MD until 9 hours before the recording. (F) DMCM treatment was performed at P17-P21. Raincloud plots show the OD distribution after MD in nontreated (noDMCM, n = 482 (all), the same data as P21 KO-MD in <xref ref-type=Figure 2 A) and DMCM-treated DGLα-KO mice (DMCM, n = 619 (all), 79 (L2/3), 91 (L4), and 266 (L5) units in 6 mice). (G) DMCM treatment was performed at P13-P17. Raincloud plots show the OD distribution after MD in nontreated (noDMCM, n = 526 (all), the same data as P17 KO-MD in Figure 2 A) and DMCM-treated DGLα-KO mice (DMCM, n = 473 (all), 96 (L2/3), 60 (L4), and 186 (L5) units in 6 mice). (H) A cannabinoid receptor agonist, WIN was injected into DGLα-KO mice intraperitoneally during MD until the day before the recording experiment. (I) OD distributions of WIN-treated DGLα-KO mice without MD (noMD, n = 498 (all), 81 (L2/3), 66 (L4), and 203 (L5) units in 5 mice) and with MD (MD, n = 589 (all), 133 (L2/3), 114 (L4), and 201 (L5) units in 6 mice). Permutation test was performed in (C), (D), (F), (G) and (I) (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). See also Figure S3 . " title="... bars indicate mean and 95% CI, respectively. (E) DMCM, an inverse agonist of the GABA A receptor, ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Measurement of inhibitory synaptic transmission in slice preparations and effects of drug administration on OD plasticity in DGLα-KO mice (A) Whole-cell patch-clamp recording was performed in L2/3 and L4 pyramidal neurons in mouse V1 slices. (B) Representative mIPSC traces from L2/3 (P17) and L4 (P21) in wild-type and DGLα-KO mice. (C and D) mIPSC frequency (C) and amplitude (D) in L2/3 (WT, n = 28 (P17), 17 (P21), and 16 (P26) cells; KO, n = 31 (P17), 17 (P21), and 13 (P26) cells) and in L4 (WT, n = 25 (P17), 23 (P21), and 21 (P26) cells; KO, n = 25 (P17), 16 (P21), and 14 (P26) cells). Colored circles show data from individual cells. The black horizontal bar and error bars indicate mean and 95% CI, respectively. (E) DMCM, an inverse agonist of the GABA A receptor, was intraperitoneally injected into DGLα-KO mice during MD until 9 hours before the recording. (F) DMCM treatment was performed at P17-P21. Raincloud plots show the OD distribution after MD in nontreated (noDMCM, n = 482 (all), the same data as P21 KO-MD in Figure 2 A) and DMCM-treated DGLα-KO mice (DMCM, n = 619 (all), 79 (L2/3), 91 (L4), and 266 (L5) units in 6 mice). (G) DMCM treatment was performed at P13-P17. Raincloud plots show the OD distribution after MD in nontreated (noDMCM, n = 526 (all), the same data as P17 KO-MD in Figure 2 A) and DMCM-treated DGLα-KO mice (DMCM, n = 473 (all), 96 (L2/3), 60 (L4), and 186 (L5) units in 6 mice). (H) A cannabinoid receptor agonist, WIN was injected into DGLα-KO mice intraperitoneally during MD until the day before the recording experiment. (I) OD distributions of WIN-treated DGLα-KO mice without MD (noMD, n = 498 (all), 81 (L2/3), 66 (L4), and 203 (L5) units in 5 mice) and with MD (MD, n = 589 (all), 133 (L2/3), 114 (L4), and 201 (L5) units in 6 mice). Permutation test was performed in (C), (D), (F), (G) and (I) (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). See also Figure S3 .

    Techniques Used: Transmission Assay, Patch Clamp, Injection


    Figure Legend Snippet:

    Techniques Used: Plasmid Preparation, Recombinant, Knock-Out, Software



    Similar Products

    Image Search Results